



**Director, Pediatric Blood and Marrow Transplantation  
Nationwide Children's Hospital  
Columbus, Ohio**

*"Improving patient outcomes by transforming transplant care"*

**THE SEARCH**

[Nationwide Children's Hospital](#) (Nationwide Children's) and The Ohio State University (Ohio State or OSU) seek applications and nominations for the position of director, Pediatric [Blood and Marrow Transplantation](#) (BMT) within [the Hematology, Oncology, & Blood and Marrow Transplant](#) division of the Department of Pediatrics. The BMT program is embedded within the larger division comprised of 55+ hematology/oncology providers. The director will join a highly dedicated and forward-thinking team focused on providing excellence in care based on discovery that readily translates research from the bench to initiatives at the bedside. The next director will play a crucial role in expanding the reach of Nationwide Children's innovative clinical care and state-of-the-art research to improve care and treatment for patients both nationally and internationally.

Nationwide Children's has a state-of-the-art, 42-bed, inpatient pediatric hematology/oncology unit – with 12 beds dedicated to BMT – that enables the BMT team to provide holistic, cutting-edge, and personalized treatment approaches for each patient. The underpinning of the program is to utilize hematopoietic cell transplantation as the definitive cure for pediatric and young adults with malignant and non-malignant disorders, while reducing transplant-associated morbidity and mortality through novel therapies and approaches in patient care.

The next director will join a strong, 22-person BMT team at a pivotal moment. As Nationwide Children's aims to position itself as a national and international leader in blood and marrow transplantation in clinical care and research, the director will serve as the face of the program regionally, nationally, and internationally. While fostering breakthrough scientific discoveries in pediatric blood and marrow transplants and advancing foundational knowledge in the field, the director will recognize the high emotional toll and personal commitment required in this work, and will proactively support the team by providing strategic vision and advocacy to unite around common goals. The director will view all members of the BMT team as vital to the success of the program, equally valuing and championing physicians, nurse practitioners, patient coordinators, psychosocial supportive care, and pharmacy providers.

Leading the day-to-day operations of the program, the director will report to the Division (academic) and Section (quality and safety) Chiefs of the Division of Hematology, Oncology, and Blood & Marrow Transplantation. The director's overarching goal is to ensure the delivery of elite and personalized clinical care through the expansion of collaborative, world-class research. To achieve these aims, the director will: inspire, unite, support, and energize the BMT team; recruit, retain, and develop talent; embrace and

strengthen a culture of inclusivity and commitment to diversity; expand innovative clinical services; support and elevate pathbreaking research; and facilitate collaborations across the enterprise.

Nationwide Children's Hospital has retained Isaacson, Miller, a national executive search firm, to assist with this important recruitment. Confidential inquiries, nominations, and applications may be directed to the firm, as indicated at the end of this document. For more information on the leadership of the hospital and the BMT program, please see the Appendix.

## **NATIONWIDE CHILDREN'S HOSPITAL**

Founded in 1892, Nationwide Children's Hospital has steadily evolved into one of the leading children's hospitals in the nation and has been named a *US News and World Report* Top 10 Honor Roll "Best Children's Hospital" for the past eight years. As one of America's largest not-for-profit, freestanding, pediatric healthcare systems, Nationwide Children's Hospital provides wellness, preventive, and diagnostic treatment, as well as rehabilitative care for infants, children, adolescents, and adult patients with congenital disease. With more than 1,000 faculty working in over 100 subspecialties and 14 research centers, Nationwide Children's clinical innovations and research serve children not just from Ohio but also from around the world.

In 2020, Nationwide Children's provided more than 1,300,000 patient visits at both the main campus and across all of its numerous satellite locations. As a leading academic medical center, Nationwide Children's trains the next generation of pediatricians, pediatric surgeons, pediatric specialists, and research scientists in partnership with the Department of Pediatrics and the Department of Surgery at The Ohio State University College of Medicine.

In June 2021, Nationwide Children's announced an aggressive, progressive, five-year, \$3.3 billion [strategic plan](#) to address the health of the whole child in a unique care model that emphasizes the integration of research and clinical care. The plan leverages recent, differentiating investments in genomics, population health, health equity, and behavioral health, positioning Nationwide Children's to take on a leadership role nationally in defining and influencing the future of pediatric healthcare and health promotion.

Beyond its walls, Nationwide Children's Hospital invests in building social equity within its communities, addressing the social determinants of health, and developing payment models to better serve unique populations of children. Its unparalleled investment in genomics and behavioral health services and research lends further credence to its role as an ambitious champion for the well-being of children everywhere. In alignment with that commitment, [diversity, equity, and inclusion](#) are cornerstone values, and advancing them is an essential part of the hospital's work. Rather than approaching this framework as a short-term project with a finish line or end date, Nationwide Children's Hospital is committed to an indefinite, ever-evolving evaluation of the institution.

Guided by the motto "Everyone Matters," Nationwide Children's Hospital has built an inclusive culture, enabling employees to bring their unique differences and talents to work every day. In recognition of success in this realm, Nationwide Children's was named to Forbes's 2021 America's Best Employers for Diversity list and has been designated a Top Hospital for Diversity by BlackDoctor.org (2019 and 2020) and a LGBTQ Healthcare Equality Index Leader by the Human Rights Campaign Foundation (2021 and 2022). The Ohio Commission on Hispanic/Latino Affairs also awarded the institution the Nuestra Familia Award (2019).

## **The HEMATOLOGY, ONCOLOGY, & BLOOD AND MARROW TRANSPLANT DIVISION**

The Hematology, Oncology, & Blood and Marrow Transplant Division (Hematology/Oncology & BMT) is one of the largest in the United States. It is a [national marrow donor program center](#) and a member of the [Children's Oncology Group](#) as well as a dozen other clinical trial consortia, several for which it serves as a coordinating center.

Each year, nearly 200 patients are diagnosed with cancer at Nationwide Children's. The Hematology/Oncology & BMT division at Nationwide Children's offers world-class diagnostic, treatment, and research facilities that provide comprehensive, multidisciplinary care for patients with cancer and acute and chronic blood disorders.

Throughout the course of care, Hematology/Oncology patients and their families need support and services that go beyond their child's medical needs. Hematology/Oncology & BMT have inpatient facilities and services that include HEPA-filtered, positive flow rooms, a large on-site outpatient infusion area, access to rapid on-unit medications and supplies, a family kitchen and a dining area with personalized food lockers, a family lounge area, and a resource library. Outpatient services include a day hospital, comprehensive clinics, dedicated telehealth nurses, pediatric home care and hospice, and emergency services.

## **THE BLOOD AND MARROW TRANSPLANT PROGRAM**

### Overview

The Pediatric Blood and Marrow Transplant Program (BMT) is at the core of the pediatric Hematology/Oncology & BMT division. From central nervous system malignancies and leukemia to nonmalignant hematologic disorders and inherited metabolic disorders, BMT is intricately involved in – and committed to – bringing the best outcomes to children requiring hematopoietic cell transplants. Both inpatient and ambulatory care is provided in a 12-bed, state-of-the-art transplant unit as well as ambulatory and satellite clinics. Backed by the support of the entire pediatric enterprise, including the intensive care and surgical services, Nationwide Children's BMT program is well equipped to manage and treat the most complicated cases.

Functioning as a collaborative and compassionate division, the BMT team applies individualized care and support to each patient and their family. Housed within the program are six credentialed transplant physicians, one pharmacy specialist, seven nurse practitioners, four patient coordinators, and a social worker, a clinical psychologist, and a palliative care physician who provide psychosocial support services – all towards proactively and holistically addressing the unique needs of each patient and the families who care for them.

To ensure this support, staff within the BMT team provide art, music, and massage therapies, as well as educational programs, family, and sibling support groups, help with navigating health insurance, and advanced illness management. The program offers specialized laboratory services that support the clinical and research teams by enabling in-house access to testing and diagnostics.

### A Comprehensive Approach to Research and Care

The BMT Program is built upon three translational research pillars: supportive care, the Host Defense Program, and the Cellular Therapy Program. By integrating care, research, and collaboration at all levels, the program elevates opportunities for the best patient outcomes while advancing the field.

A team of researchers, physicians, nurses, and support staff focuses on treating and preventing infection, late effects, and organ toxicity. As a site for pharmaceutical trials and protocol development in each of these areas, the program leads multiple BMT-specific quality improvement projects that ensure patients have every opportunity for the best possible outcomes. Between 2017-2021, the BMT program conducted 311 total transplants, with a 95.2% survival rate at 100 days post-transplant for all diseases and transplant types. During the same timeframe, the survival rate for malignant allogeneic transplants was 92.2% 100 days post-transplant.

### The Cellular Therapy and Cancer Immunology Program

[The Cellular Therapy and Cancer Immunology Program](#) at Nationwide Children's and The Ohio State University Comprehensive Cancer Center works synergistically with the BMT program. Through combined clinical trials, collaborative treatment protocols, and a one-team approach to patient care, experts in cellular therapy and BMT are offering next-level opportunities for the best outcomes. Advanced cellular therapy uses knowledge of the immune system and the transplant process to target specific cells to prevent or reduce GvHD, infection, and disease relapse. The implications of cellular therapy are broad, and further development and refinement in this field will directly impact children everywhere.

In particular, investigators within the [Center for Childhood Cancer & Blood Diseases at Nationwide Children's Abigail Wexner Research Institute \(AWRI\)](#) focus on developing and testing new, targeted therapies. Simultaneously, Hem/Onc clinical faculty create cell therapy-related clinical trials. Hem/Onc and ID investigators have experienced significant success with Investigational New Drug (IND) application approvals, creating clinical trials, and treating patients. Nineteen new trials opened in 2021.

At present, Nationwide Children's is scaling up to manufacture for pediatric cell therapy trials and is currently manufacturing cell therapy products such as Imaging Flow Cytometry (IFC) and Natural Killer (NK) cells. Both OSU and Nationwide Children's Hospital have GMP facilities manufacturing cell therapy products. The goal is to bring as many pediatric trials to the institution as possible. Nationwide Children's has developed an international reputation in the NK cell space, significant CAR-T experience, notable network partnerships and collaboration in multi-site trials (e.g., NANT and PNOC consortia), and highly networked families. Cell therapy at Nationwide Children's is uniquely positioned to leverage in-house expertise and assets to become a leader in allogeneic cell therapy.

For more information about additional key initiatives and educational opportunities, see [the Appendix](#).

### Education and Training in BMT at Nationwide Children's Hospital

The Pediatric BMT and Cellular Therapy Fellowship Program at Nationwide Children's offers a one-year fellowship for qualified physicians who completed a basic, three-year program in pediatric Hem/Onc and wish to pursue further training in pediatric blood and marrow transplantation.

The program trains physicians in indications for transplant; pre-transplant patient evaluation; identification and selection of stem cell sources; use of donor registries; methodologies of HLA typing; marrow cryopreservation; management of ABO incompatible cell products; administration of high-dose chemotherapy; management of neutropenic fever; management of bacterial/viral/fungal diseases in immunocompromised patients; management of bleeding diathesis; diagnosis and management of regimen-related toxicities; diagnosis and management of acute and chronic graft-versus-host disease; late complications of marrow transplantation; terminal care; and training in documentation and reporting for patients treated in investigational trials.

Trainees gain experience in bone marrow harvest, stem cell apheresis, stem cell product infusions, and advanced cell processing techniques. Trainees are also encouraged to participate in protocol design and development and to complete a clinical research project related to transplantation.

### The Host Defense Program

A collaboration between the Divisions of Hematology/Oncology & BMT and Infectious Diseases, [the Host Defense Program \(HDP\)](#) offers a unique approach to reducing infection-related morbidity and mortality in immunocompromised patients through novel therapeutics.

The HDP Team is comprised of board-certified Infectious Disease subspecialists with expertise in caring for children and young adults with compromised immune systems, particularly patients receiving hematopoietic cell therapies and transplants. HDP team members are integrated into subspecialty teams, providing clinical expertise and a continuum of infection-related care in both hospital and ambulatory settings. The HDP develops evidence-based, best clinical practice standards to optimize patient outcomes related to the prevention and treatment of infections. Team members also participate in multi-institutional clinical trials that give patients access to cutting-edge diagnostics and therapies, including new antimicrobial agents directed against drug-resistant bacteria, invasive fungi, and viruses.

### Looking Ahead

The Hematology, Oncology, and Blood & Marrow Transplant division is currently thinking broadly about its strategic direction and is in the early stages of crafting a 2022-2025 strategic plan. The incoming director will contribute to this vision, in concert with the senior leadership team. Overall, the program aims to drive best outcomes for all patients by creating a nationally and internationally lauded Hematology, Oncology and Blood and Marrow Transplant clinical program based on and informed by translational research, in alignment with the overall strategic goals of Nationwide Children's. The program will establish itself as a center for national expertise, scaling the reach and impact of existing and new programs, while developing leading models of pediatric health care.

To achieve its vision of preeminence, the division will invest in the following areas:

- Addressing issues related to wellness and population health
- Ensuring excellence in quality, safety, and patient experience initiatives
- Continuing and expanding ground-breaking research
- Building upon current – and establishing new – meaningful partnerships

- Identifying, educating, and retaining diverse and inclusive talent working in tandem in an equitable environment for all..

In particular, the division aims to: advance clinical programs by growing outpatient volume and increasing the number of new and multidisciplinary clinics; establish destination programs for out-of-state and international patients; collaborate with the Institute for Genomic Medicine (IGM); expand non-traditional care delivery models; better leverage technology; drive best outcomes for every patient; examine how health equity impacts patient outcomes; develop clinical trials and research in targeted areas; recruit scientists to aid in treatment discovery; and strengthen overall research infrastructure as it pertains to mentoring and career development.

## **THE ROLE**

The director will report to Dr. Timothy Cripe, Division Chief for the Division of Hematology/Oncology/Blood & Marrow Transplant, and Dr. Randal Olshefski, Section Chief. While serving as an advocate for the BMT unit in ensuring its success and mission of excellence, the Director will also be a member of the Division's leadership team in striving to achieve the overall goals of the division and of Nationwide Children's.

Within that framework, the director of BMT will develop the program's strategic direction and ensuring the successful implementation of that plan. and Leading by example, the Director will provide excellent clinical care while working side by side with BMT care providers in the unit, oversee the program's planned growth and the execution of any operational adjustments as needed, actively engage with, recruit and retain care providers within the unit, and encourage and support the further development of the translational and clinical research within Nationwide's research portfolio. With a rapidly emerging national and international reputation, an excellent foundation, and a close-knit, highly dedicated and impassioned team, the director will be well-positioned – with both the required resources and requisite authority – to further build upon Nationwide's excellence in BMT care delivery.

## **LEADERSHIP OPPORTUNITIES**

Multiple opportunities exist for the director to effect true impact. Among them are the following directives:

### **Lead by example: inspire, unite, support, and energize the BMT team**

The BMT team is a compassionate, collaborative and accomplished group driven to provide the individualized, world-class care to every patient and their families. The director will be a team player who brings a deep understanding of the complexities that exist at every level of care every day. To successfully lead – and support - this group, one needs to have achieved strong academic and clinical skills, buttressed by even more highly developed emotional intelligence, and people skills. Applying a high EQ leadership style based on open and transparent communication principles, will build trust and establish a safe environment in which all feel valued and equally important in the overall delivery of care models. To achieve this culture of transparency and safety, the director will be a highly engaged champion and advocate for the BMT care team.

### **Facilitate collaborations across the enterprise**

The next director will be a critical partner to division chiefs, department chairs, and other senior leaders in facilitating possible alignment and any required restructuring. Fostering collaborations that enable the translation of pathbreaking research into clinical trials, the director will help develop the strong, interdisciplinary relationships pivotal to the success of the program.

### **Assess, evaluate, and expand innovative clinical services as needed**

The director will at all times ensure the delivery of excellent care, ease of access, and the highest quality outcomes for patients in a highly competitive, complex, and uncertain healthcare environment. Doing so includes meeting the growing demands and needs of the Columbus and central Ohio community and supporting the expansion of regional networks and partnerships. To do so successfully, the director will need to maintain a keen eye on staffing, and operational efficiencies to ensure uncompromised, high-quality institutional patient safety outcomes and initiatives. Simultaneously, the director will also strive to help Nationwide Children's achieve the right balance between acting locally and developing the horsepower and responsibility to achieve globally. Amidst this work, the director will support uncompromised, high-quality institutional patient safety initiatives.

### **Recruit, retain, and develop talent**

The director will develop and nurture emerging and established talent, ensuring a robust and diverse pipeline of clinical and scientific leaders who confront the most profound questions and challenges in blood and marrow transplantation. Critical to the program's mission, the director must work relentlessly to hire and keep the very best talent through research collaborations, investment, and the creation of a satisfying working environment. The director will, in collaboration with the team, establish cultural and deliverable norms that create a flexible work/life balance, ensure an even distribution of workload and responsibility, and support the team's need to recharge.

### **Embrace and strengthen a culture of inclusivity and commitment to diversity**

Nationwide Children's strives to live values of diversity, equity, and inclusion within its walls and as a member of a vibrant community. The director will move with urgency to promote inclusion and diversity both internally and externally, hiring at all levels from backgrounds underrepresented in medicine, ensuring strong professional development and career progression for all team members, and proactively shaping a culture that enables teamwide success.

### **Support and elevate pathbreaking research**

The BMT program promotes breakthrough research with a global reach. The director's ability to encourage and inspire faculty research and to support discovery will define success for decades to come. It will require that the director assesses and considers infrastructure and resource needs and advocates accordingly to procure what is needed to help scientists reach these heights. This will require well-honed strategizing toward achieving powerful investments in clinical trials. At all times, the director will balance fiscal responsibility with a willingness to take risks and bet on exciting new initiatives.



## THE SUCCESSFUL CANDIDATE

The director of BMT at Nationwide Children's Hospital is a highly significant leadership role at one of the leading pediatric healthcare institutions in the world. The next director must possess proven collaborative leadership style within a complex academic medical environment that includes both clinical and research experience, and uncompromising integrity and ethics. A board-certified, pediatric MD is required. In addition, the candidate must meet the requirements for appointment as a Full Professor in the Tenured or Clinical track at The Ohio State University and be eligible for licensure in the state of Ohio.

The successful candidate will show evidence of many of the following personal qualities and professional experiences:

- An uncompromising commitment to excellence in the three-pronged mission of pediatric academic medicine; clinical care, medical education, and research.
- An established record of increasingly responsible leadership experience along with a strong scholarly achievement.
- Ability to develop a collaborative vision, with a track record of successfully implementing in an academic medical center, new initiatives across clinical care, research, and faculty development.
- An outstanding record of effectively leading and developing people; a strong team orientation, along with a track record of working cooperatively and collegially within a diverse and complex environment
- Proven administrative management experience, including financial budgeting, resource management, planning, and facilitation skills
- Demonstrated experience in recruiting, retaining, and mentoring top faculty and/or students based on an innate commitment to valuing and actively promoting diversity
- Excellent interpersonal and communication skills; the ability to build trust while also engaging, challenging and influencing colleagues to effect change within a dynamic organization
- An entrepreneurial spirit and drive; willingness to take risks and advocate for new ideas, coupled with a commitment to measurement and accountability
- Personal qualities that include a present and optimistic personality, integrity, creativity, resilience, flexibility, tenacity, transparency, and high energy; a high level of emotional intelligence is crucial
- Genuine understanding of and respect for the tradition of collaborative science at Nationwide Children's Hospital

## TO APPLY

Inquiries, nominations, and applications should be sent in strict confidence to:

Patricia Hastie, Partner  
Berkley Burke, Senior Associate  
Stephanie Simon, Associate  
Isaacson, Miller

<https://www.imsearch.com/search-detail/S8-459>

*Nationwide Children's Hospital is an equal opportunity employer that values diversity.  
Candidates of diverse backgrounds are encouraged to apply.*



## APPENDIX

### NATIONWIDE CHILDREN'S LEADERSHIP

Tim Robinson, Chief Executive Officer, Nationwide Children's Hospital:

[Dr. Robinson](#) is the Chief Executive Officer of Nationwide Children's Hospital. Mr. Robinson first joined Nationwide Children's in 1995 and has helped the hospital transform from an important regional children's health care system into a preeminent academic medical center. In his 25 years with Nationwide Children's, Mr. Robinson has held the titles of assistant treasurer, senior vice president, executive vice president, and chief financial and administrative officer. He is credited with building the hospital's investment portfolio from \$100 million to almost \$3 billion and leading the hospital to earn an Aa2 bond rating consistently since 2001.

Dr. Dennis Durbin, President, The Abigail Wexner Research Institute:

As president of AWRI, [Dr. Durbin](#) oversees the vision and strategic direction for the research institute, including the further integration of research and clinical care at Nationwide Children's as highlighted in the hospital's recently announced new five-year strategic plan. Dr. Durbin represents the research institute in its ever-growing relationship with The Ohio State University and with the evolving biotechnology ecosystem developing in central Ohio. He also continues to support the recruitment of basic scientists; clinical investigators; and behavioral health and health equity researchers to AWRI. Previously, as AWRI's first CSO, Dr. Durbin managed a broad portfolio of research initiatives including the formation of Andelyn Biosciences, the hospital's first chief clinical research officer position, currently held by pediatric surgeon Kate Deans, MD; the recruitment of over 40 new research-intensive faculty; and the construction of a fourth research building on the Nationwide Children's campus, scheduled to open in 2023.

Prior to joining Nationwide Children's in early 2018, Dr. Durbin was a professor of pediatrics at the University of Pennsylvania and served as assistant vice president and chief clinical research officer at The Children's Hospital of Philadelphia Research Institute. On the faculty there for 20 years, Dr. Durbin was also an associate scholar in the Center for Clinical Epidemiology and Biostatistics. He is an internationally recognized injury epidemiologist whose research has focused on the prevention of motor vehicle occupant injuries to children and the prevention of teen-driver crashes.

Dr. Timothy Cripe, Chief of the Division of Hematology/Oncology/BMT:

[Dr. Cripe](#), MD, Ph.D., FAAP, is chief of the Division of Hematology and Oncology at Nationwide Children's Hospital, a Gordon Teter Endowed Chair in Pediatric Cancer at Nationwide Children's Hospital, and a professor of pediatrics at The Ohio State University. Dr. Cripe received his undergraduate degree in Biochemistry from Princeton University and his M.D. and Ph.D. in Genetics from the University of Iowa. He completed his pediatric residency training at the University of Iowa Children's Hospital and his subspecialty fellowship training in pediatric hematology/oncology from Dana-Farber Cancer Institute/Children's Hospital, Boston, and the University of Colorado/Children's Hospital, Denver. He was on faculty at the University of Wisconsin-Madison and Cincinnati Children's Hospital before coming to Nationwide Children's.

Dr. Randal Olshefski, Section Chief, Division of Hematology/Oncology/BMT:

As Section Chief, [Dr. Olshefski](#) represents the Division of Hematology/Oncology/BMT in the numerous Quality and Patient-Safety initiatives that touch patients with cancer and blood disorders. In addition, he

works closely with the medical and nursing leadership at the division and hospital level to improve patient experience. Dr. Olshefski is the medical director of the multi-disciplinary Cancer Survivorship clinic at Nationwide Children's Hospital. His clinical interests include the long-term outcome of childhood cancer survivors, focusing on late effects of treatment.

## **ABOUT THE BMT PROGRAM - KEY INITIATIVES**

### TEMPO (Transplant Energize Me Patient Outcome) Initiative

Patients with prolonged hospitalizations often experience significant physical deconditioning caused by inactivity. The BMT program has partnered with Clinical Therapy Services and Psychosocial Services to establish a standard-of-care approach to work with children during their transplant admissions. At the time of admission, team members work with families to establish physical, mental, and social goals for each child. By actively participating with therapy teams daily, children have the opportunity to achieve their best functional outcome at discharge.

### BMT Long-Term Follow-Up Clinic

While BMT aims to reduce side effects as much as possible, patients who have had a transplant need to remain connected to expert care. The BMT Long-Term Follow-Up Clinic focuses on the needs of children, adolescents, and adults who have undergone haemopoietic stem cell transplant (HSCT) and are at least two years post-transplant. The main focus of this comprehensive, multidisciplinary clinic is to look for long-term complications of BMT, such as growth failure, endocrine organ dysfunction, fertility concerns, dental issues, and psychological and social concerns. Experts in all of these areas are available to patients in one clinic visit to meet whatever needs patients may have. Patients receive a summary of their treatment and educational information about potential complications of their disease or treatment, along with recommendations for screening and maintaining a healthy lifestyle.

### Apheresis at Nationwide Children's

BMT's apheresis team offers several advanced therapies, including extracorporeal photopheresis, red cell exchange, therapeutic plasma exchange, and leukopheresis or leucodepletion.

The apheresis team is also essential to supporting cellular therapy operations. By working closely with cellular therapy experts, they can perform procedures needed to acquire the needed cells with unparalleled efficiency and effectiveness.

## **ORGANIZATIONAL STRUCTURE OF THE ENTERPRISE**

### The College of Medicine

For more than a century, The Ohio State University College of Medicine has been a leader in [innovative programs, initiatives, and curricula](#). As one of the largest and most diverse academic medical centers in the country, OSU has trained more than 20,000 physicians and countless thousands of other affiliated healthcare professionals. The College of Medicine features 19 clinical departments, seven basic science departments, and an outstanding [School of Health and Rehabilitation Sciences](#) offering undergraduate degrees, master's degrees, and Ph.D. programs.

### The Wexner Medical Center

[The Ohio State Wexner Medical Center](#), located in one of the most comprehensive health sciences campuses in America – with colleges of Medicine, Nursing, Pharmacy, Dentistry, Optometry, Public Health, and Veterinary Medicine in close proximity – is part of The Ohio State University campus. This proximity fosters collaborations with other university departments, making OSU unique in its potential to promote scientific partnerships and direct translation of research discoveries into new medical therapies and technologies. The Center offers dual-degree programs, such as MD/MBA, MD/JD, MD/Ph.D., and MD/MHA, in collaboration with the Fisher College of Business, the College of Law, and the College of Public Health.

As the only academic medical center in central Ohio, The Wexner Medical Center is at the forefront of medicine, where discovery and innovation in research laboratories make unique, effective therapies available to patients in months, even years, before other hospitals. These initiatives are taking place within Ohio State's College of Medicine, more than a dozen affiliated research centers, and seven hospitals.

### The Comprehensive Cancer Center

[The Ohio State University Comprehensive Cancer Center](#) – [Arthur G. James Cancer Hospital and Richard J. Solove Research Institute](#) – is a dedicated cancer hospital and research center. The OSUCCC-James is one of only 49 National Cancer Institute-designated comprehensive cancer centers and one of only a few centers conducting NCI-sponsored phase I and phase II clinical trials on novel anticancer agents.

### **THE ENVIRONMENT: COLUMBUS, OHIO**

Columbus – the state capital of Ohio – is the second-largest city in the Midwest and the fourteenth most populous city in the United States. It is a global city fueled by a highly educated workforce and a diverse mix of ethnicities and foreign-born residents. Over the last five years, the Columbus Region has granted over 8,700 degrees in biology, biomedical science, chemistry, and pharmacy, and The Ohio State University ranks in the top 10 nationally in Biological and Biomedical Science Ph.D. completions.

A key differentiator that sets Columbus apart is the "[Columbus Way](#)" – the practice of community stewardship, anchored by a set of values and principles that power progress in the region. These values include ambition, collaboration, fellowship, inclusivity, and the common good.

Columbus Accolades:

- One of the 10 Best Big Cities to Live in Right Now (*TIME* magazine)
- #1 Opportunity City (*Forbes*)
- #1 Top City for Rising Tech Start-Ups (*Forbes*)
- Top 8 Cities That Are Essential to the Future of American Innovation (*Entrepreneur*)
- Best American City to Work in Tech (*Smart Asset*)
- One of the "30 Most Fun Places to Live in the U.S." (*U.S. News & World Report*)

Living in Columbus At-A-Glance:

- 77% of homes sold are affordable to the median household income
- \$1,269 median monthly rent in downtown

- \$278,603 average home sale price
- Cost of Living Index = 90.8
- Average Commute = 24 minutes
- Top 10 lowest violent crime rates among large metro areas
- Top 50 Best Biking Cities in America with 230 miles of Central Ohio Greenways trails
- Over 400 Metro Parks
- More than 50 colleges and universities
- The Columbus Region has earned a national reputation for its energetic blend of arts and culture: the [No. 1 zoo](#), the [No. 1 science center](#), the [No. 1 public library](#), and even the [No. 1 ice cream](#); A best American City for Live Music (*Reader's Digest*); Home to more fashion designers than any U.S. city, outside of New York and Los Angeles.
- Sports teams for every season: Columbus Crew SC (MLS), Columbus Blue Jackets (NHL), Columbus Clippers (MiLB), and Ohio State Buckeyes

Learn more about Columbus through the [Experience Columbus Visitor Guide](#) and more about relocation to Columbus through the [Experience Columbus Relocation Guide](#).